Anavex Life Sciences Corporation

NASDAQ:AVXL   3:23:12 PM EDT
17.55
+0.58 (+3.42%)
Products, Regulatory

Anavex Life Sciences Announces Publication Of Foundational Data For ANAVEX2-73 In Fragile X Syndrome (Autism)

Published: 08/26/2021 11:18 GMT
Anavex Life Sciences Corporation (AVXL) - Anavex Life Sciences Announces Publication of Foundational Data for Anavex®2-73 (blarcamesine) in Fragile X Syndrome (autism).
Anavex Life Sciences Corp - Positron Emission Tomography (pet) Establishes Anavex®2-73's Dose Dependent Sigmar1 Receptor Occupancy.
Anavex Life Sciences Corp - Study Provides Proof-of-concept for Advancing Anavex®2-73 (blarcamesine) Into Phase 2/3 Fragile X Syndrome Clinical Trial.